Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Bowker, Karen E ^a   Noel, Alan R ^a   MacGowan, Alasdair P ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; ANTIBIOTIC RESISTANCE; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; STAPHYLOCOCCUS INFECTION; THEORETICAL MODEL;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, THEORETICAL; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 73949110796     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp289     Document Type: Article

References (38)

1. Fowler VJ Jr, Sakoulas G, McIntyre LM et al. Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004; 190: 1140-9.
2. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8.
3. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Microbiol 2004; 42: 2398-402.
4. Moise-Broder PA, Sakoulas G, Eliopoulous GM et al. Accessory gene regulator II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-5.
5. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. Clin Infect Dis 2007; 46: 193-200.
6. Cha R, Brown WJ, Rybak MJ. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycinresistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2003; 47: 3960-3.
7. Louie A, Kaw P, Liu W et al. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001; 45: 845-51.
8. Cha R, Rybak MJ. Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. J Antimicrob Chemother 2004; 54: 259-62.
9. Alder J, Li T, Yu D et al. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection. Antimicrob Agents Chemother 2003; 47: 3561-6.
10. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48: 63-8.
11. Dvorchik BH, Brazier D, DeBruin MF et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-23.
12. Dvorchik B, Arbeit RD, Chung J et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004; 48: 2799-807.
13. Benvenuto M, Benziger DP, Yankelev S et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in volunteers. Antimicrob Agents Chemother 2006; 50: 3245-9.
14. Dahl-Knudsen J, Fuursted K, Raber S et al. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000; 44: 1247-54.
15. Turner J, Howe RA, Wootton M et al. The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model. J Antimicrob Chemother 2001; 48: 727-30.
16. Odenholt I, Löwdin E, Cars O. In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium. Clin Microbiol Infect 2003; 9: 930-7.
17. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
18. Lortholary O, Tod M, Rizzo N et al. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother 1996; 40: 1242-7.
19. Bowker KE, Wootton M, Rogers CA et al. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. J Antimicrob Chemother 1999; 44: 661-7.
20. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48 Suppl 1: 5-16.
21. Clinical and Laboratory Standards Institute. Methods for Dilution Susceptibility Tests for Bacteria That Grow Aerobically-Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
22. Andrews JM. Microbiological assays. In: Reeves DS, Wise R, Andrews JM et al., eds. Clinical Antimicrobial Assays. Oxford: Oxford University Press, 1999; 45-64.
23. Marco F, de la Mària C, Armero Y et al. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2538-43.
24. Löwdin E, Cars O, Odenholt I. Pharmacodynamic studies of daptomycin against staphylococci in an in vitro kinetic model and in a foreign body model. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2006. Abstract A-645, p. 16. American Society for Microbiology, Washington, DC, USA.
25. LaPlante KL, Leonard SN, Andes DR et al. Activities of clindamycin, doxycycline, linezolid, trimethoprim-sulphamethoxazole, and vancomycin against community acquired methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother 2008; 52: 2156-62.
26. Kaatz GW, Seo SM, Reddy VN et al. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1990; 34: 2081-5.
27. Huang JH, Hsu RB. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study. Scand J Infect Dis 2008; 40: 462-7.
28. Dandekar PK, Tessier PR, Williams P et al. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillinresistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003; 52: 405-11.
29. Akins R, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45: 454-9.
30. European Committee on Antimicrobial Susceptibility Testing (EUCAST). http://www.eucast.org (3 March 2009, date last accessed).
31. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA, USA, 2009.
32. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST technical note on daptomycin. Clin Microbial Infect 2006; 12: 599-601.
33. Hirschwerk D, Ginocchio C, Bythrow M et al. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteraemia. Infect Control Hosp Epidemiol 2006; 27: 315-7.
34. Mangili A, Bica I, Snydman D et al. Daptomycin-resistant methicillin-resistant Staphylococcus aureus bacteraemia. Clin Infect Dis 2005; 40: 1058-60.
35. Gqada Z, Marais B, Wasseraman E et al. Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing non-susceptibility to daptomycin. J Clin Microbiol 2008; 46: 220-4.
36. Sakoulas G, Alder J, Thauvin-Eliopoulsa C et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-5.
37. Camargo IL, Neoh HM, Cui L et al. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob Agents Chemother 2008; 52: 4289-99.
38. Rose WE, Leonard SN, Sakoulas G et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52: 831-6.